OptimizeRx (NASDAQ:OPRX) vs. Ucommune International (NASDAQ:UK) Financial Survey

Ucommune International (NASDAQ:UK) and OptimizeRx (NASDAQ:OPRX) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Valuation & Earnings

This table compares Ucommune International and OptimizeRx”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ucommune International	$64.76 million	0.01	-$690,000.00	N/A	N/A
OptimizeRx	$71.52 million	1.24	-$17.57 million	($1.33)	-3.61

Ucommune International has higher earnings, but lower revenue than OptimizeRx.

Profitability

This table compares Ucommune International and OptimizeRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ucommune International	N/A	N/A	N/A
OptimizeRx	-27.41%	-4.92%	-3.41%

Institutional and Insider Ownership

36.9% of Ucommune International shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 14.2% of Ucommune International shares are owned by company insiders. Comparatively, 6.1% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Ucommune International and OptimizeRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ucommune International	0	0	0	0	0.00
OptimizeRx	0	3	6	0	2.67

OptimizeRx has a consensus target price of $9.06, suggesting a potential upside of 88.80%. Given OptimizeRx’s stronger consensus rating and higher possible upside, analysts clearly believe OptimizeRx is more favorable than Ucommune International.

Volatility & Risk

Ucommune International has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.

Summary

OptimizeRx beats Ucommune International on 7 of the 12 factors compared between the two stocks.

About Ucommune International

Ucommune International Ltd manages and provides agile office spaces in China. It operates self-operated and asset-light models. The company also provides individual services, such as catering, fitness, healthcare, training, and entertainment; general corporate services, such as corporate secretary, human resources, legal, finance, IT support, and tax services; incubation and corporate venturing services; design and build services; advertising and branding services; and related services. It serves individuals and enterprises. The company operates under the Ucommune brand. Ucommune International Ltd was founded in 2015 and is based in Beijing, the People's Republic of China.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.